The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

February 15, 2023 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture, as well as adult patients for whom other osteoporosis therapies have proved ineffective or can’t tolerate other therapies.1

You Might Also Like
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
Also By This Author
  • Baricitinib Has Promising Clinical Trial Results for Treating RA

The FDA had previously approved abaloparatide for the treatment of postmenopausal women with osteoporosis at high risk of fracture.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abaloparatide is an analog of parathyroid hormone-related peptide [PTHrP(1-34)].3 High fracture risk is defined as a history of osteoporotic fracture or multiple risk factors for fracture, such as age, low bone mineral density (BMD) and previous fragility fracture.4

This latest FDA approval was based on findings of a 12-month, safety and efficacy study of subcutaneous abaloparatide in men with osteoporosis (ATOM; NCT03512262).5 The multicenter, phase 3 study was randomized and double-blinded.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, researchers evaluated 80 μg of abaloparatide given daily as a subcutaneous injection to men with osteoporosis (n=149) aged 40–85 years old. This group was compared with a group of men with osteoporosis who received placebo injections (n=79). All patients also took daily supplemental calcium (500–1,000 mg) and vitamin D (400–800 IU).

The study’s primary outcome measure was the change in percentage from baseline in BMD of the lumbar spine at month 12. Secondary outcome measures were the change in percentage from baseline in BMD of the total hip and femoral neck at month 12, the change in percentage from baseline in BMD of the lumbar spine at month six and treatment-associated emergent adverse events associated with hypercalcemia within 13 months.

Results

Most men in the study were white (approximately 95%); 4% were Asian, and 0.4% were Black. Another 16% of study patients identified as Hispanic. At baseline, mean T-scores at the lumbar spine and femoral neck were -2.1, and mean T-scores at the total hip were -1.7.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

At month 12, treatment with abaloparatide had led to significant increases in BMD at the lumbar spine, total hip and femoral neck (P<0.0001), compared with placebo. For the primary efficacy measure of the lumbar spine, the change in percentage in BMD from baseline was 8.5% for patients treated with abaloparatide and 1.2% for patients who received the placebo—a 7.3% treatment difference (99% confidence interval [CI] 5.1%, 9.6%; P<0.0001). No differences in the effect of abaloparatide were seen across subgroups defined by ethnicity, race, age, geographic region, BMD at baseline or the presence or absence of prior fracture.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: abaloparatide, FDA, FDA approval, Osteoporosis, osteoporosis treatments, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)